Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||gain of function|
|Gene Variant Descriptions||ALK act mut indicates that this variant results in a gain of function in the Alk protein. However, the specific amino acid change has not been identified.|
|Associated Drug Resistance|
|Category Variants Paths||
ALK mutant ALK act mut
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK act mut TP53 wild-type||neuroblastoma||predicted - sensitive||Crizotinib + Cyclophosphamide + Topotecan||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).||26438783|